|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM354368885 |
| 003 |
DE-627 |
| 005 |
20231226062054.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109290
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1181.xml
|
| 035 |
|
|
|a (DE-627)NLM354368885
|
| 035 |
|
|
|a (NLM)36931486
|
| 035 |
|
|
|a (PII)S1521-6616(23)00069-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zou, Yiping
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.04.2023
|
| 500 |
|
|
|a Date Revised 11.04.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023. Published by Elsevier Inc.
|
| 520 |
|
|
|a The value of peripheral blood lymphocyte subpopulations in predicting responses to lenvatinib combination with programmed death-1 (PD-1) inhibitors in unresectable hepatocellular carcinoma (HCC) was investigated. Fifteen patients received objective responses (OR) and sixteen patients had non-objective responses (NOR) were analyzed. The counts of peripheral blood lymphocyte subpopulations from patients were measured before treatment, second (at week 3), and third doses (at week 6) of the PD-1 inhibitor administration, and correlated with responses. Helper T (Th) cells and natural killers (NK) cells were more abundant in the OR group and found to be important predictors of OR in a stepwise multivariate logistic regression analysis. These cutoff values of Th and NK cells could help to distinguish OR from NOR cases accurately and provide clinical benefits
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Hepatocellular carcinoma
|
| 650 |
|
4 |
|a Lenvatinib
|
| 650 |
|
4 |
|a Lymphocyte
|
| 650 |
|
4 |
|a PD-1 inhibitor
|
| 650 |
|
7 |
|a lenvatinib
|2 NLM
|
| 650 |
|
7 |
|a EE083865G2
|2 NLM
|
| 650 |
|
7 |
|a Immune Checkpoint Inhibitors
|2 NLM
|
| 700 |
1 |
|
|a Chen, Zhihong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Zhenrong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Yuanpeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zheng, Zehao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Fan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Lianqun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Qiao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lin, Ye
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Ning
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jin, Haosheng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 249(2023) vom: 31. Apr., Seite 109290
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:249
|g year:2023
|g day:31
|g month:04
|g pages:109290
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109290
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 249
|j 2023
|b 31
|c 04
|h 109290
|